Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — FY2025 Earnings Presentation
29 slides from Jagsonpal Pharmaceuticals's earnings presentation, May 6, 2025
Slide 1: Cover letter to exchanges
!JAGSONPALI JAGSONPAL PHARMACEUTICALS LIMITED Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India) Ph.: +91 124 4406710; E-mail: cs@jagsonpal.com; Website: www.jagsonpal.com CIN NO. L74899DL1978PLC009181 May 6, 2025 The Department of Co
Slide 2: Jagsonpal Pharmaceuticals announces the FY25 Results
~ ~ 'l!lu ' akht D !IH5QKPAL! Jagsonpal Pharmaceuticals announces the FY25 Results Revenue at ₹2,687 Mn (up 28.8% YoY), Operating EBITDA at ₹579 Mn, margin at 21.5%, Board recommends 125% dividend (₹2.5 per Equity share) Gurugram, May 6, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE:JAGS
Slide 3: About Jagsonpal Pharmaceuticals Limited
ABOUT JAGSONPAL PHARMACEUTICALS LIMITED Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over four decades in the Indian pharmaceutical market. The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, Dermatology and Child-
Slide 4: Jagsonpal Pharmaceuticals Limited Q4FY25 & FY25
Jagsonpal Pharmaceuticals Q4FY25 & FY25 Limited Investor Presentation May 2025
Slide 5: Safe Harbor
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • Safe Harbor UAGSONPALI • • • • • • • • • • • • • • • • • • • • This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementatio
Slide 6: Q4FY25/FY25 Performance
Q4FY25/ FY25 Performance 3
Slide 7: Management Commentary
Management Commentary "We are pleased with our FY25 performance, which underscores the strength of our strategy and execution. Revenue grew 29% to Rs. 2,687 million, while operating EBITDA rose 59% to Rs. 579 million, driven by a 410 bps margin expansion— reflecting disciplined cost management and s
Slide 8: Highlights: Q4 & FY25
Highlights: Q4 & FY25 Sales Momentum Maintained Achieved Rs. 586 Mn in quarterly sales, marking a robust 34.7% growth compared to Q4FY24. Fully Integrated Acquisition – Expanding therapeutic footprint Dermatology and Pediatric segments show early momentum, validating strategic fit, minimal product o
Slide 9: Key Brand Progression (Source: IQVIA)
Key Brand Progression (Source: IQVIA) (All values in Rs. Mn) Brand MAT Dec’24 MAT Dec’23 Growth% Jagsonpal 4,120* 3,063 35% Indocap 520 430 21% Maintane Injection 380 370 3% Metadec 320 330 -3% Divatrone 230 310 -26% Lycored 280 290 -3% Endoreg 170 160 6% Maintane Tablet 150 150 - Equirex 140 140 -
Slide 10: A Growth Milestone: Indocap - First INR 50 Cr Brand
A Growth Milestone: Indocap - First INR 50 Cr Brand r------------------------------------ Strategic Fit: -------------------------------------, 1 I I I Strengthens JPL’s leadership in pain and anti-inflammatory space. I I I I .-■-■-■-■-■ r---------------------- Product Highlights 520 • Combines Indo
Slide 11: Financial Highlights: Q4 & FY25
Financial Highlights: Q4 & FY25 (All values in Rs. Mn) Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT* & Margin (%) ---■-■-■-■., ---■-■-■-■., ---■-■-■-■., ---■-■-■-■-. Q4FY24 ■ Q4FY25 586 368 435 258 97 66 49 35 59.4% 62.9% 11.3% 16.6% 8.2% 11.2% L. - . - . - . _. L. - .
Slide 12: Reported Financial Results: Q4 & FY25
Reported Financial Results: Q4 & FY25 (All values in Rs. Mn) Particulars Q4FY25 Q4FY24 Q3FY25 FY25 FY24 Revenue from Operations 586 435 740 2,687 2,087 Total Expenses 489 386 569 2,108 1,723 EBITDA 97 49 171 579 364 EBITDA Margin 16.6% 11.3% 23.1% 21.5% 17.4% Other Income 28 25 23 82 93 ESOP Cost 10
Slide 13: Key Balance Sheet Items
Key Balance Sheet Items (All values in Rs. Mn) Movement Movement Particulars 31-Mar-25 31-Mar-24 31-Dec-24 (YoY) (QoQ) Shareholders Funds 2,399 1,874 525 2,319 80 Tangible Assets 6 9 (3) 8 (2) Intangibles 856 0 856 875 (19) Right of Use Assets 82 84 (2) 86 (4) Assets Held for Sale 0 172 (172) 0 0 Fi
Slide 14: Strategic Acquisition- scales business, stronger outcome
Strategic Acquisition- scales business, stronger outcome JAGSONPAL YASH PHARMA BUSINESS Expertise Innovation Scale •Expertise •Innovation •Scale o 4 Decades of o Key Therapeutic o Strong Northern & o 5 Decades of o New segments: o Strong Eastern and Experience areas: Gynecology & Eastern presence Ex
Slide 15: Strategic Acquisition of Resilient – Called off
Strategic Acquisition of Resilient – Called off r---- 1 --- --- Background - - - -1 I 1 I On February 21, 2025 Company announced a proposed acquisition of India business of Resilient Cosme -Ceuticals I I I I Private Limited (“Resilient”), including its associated brands and trademarks. The transacti
Slide 16: JPL Reinvented: New Ownership. New Trajectory.
JPL Reinvented (2022-2025) New Ownership. New Trajectory. 13
Slide 17: A 3-Year snapshot: Strategic Injectors. Sustained Growth.
A 3-Year snapshot : Strategic Injectors. Sustained Growth. - I Expanded Therapeutic Segments I ~ I I I I I GYNEACOLOGY ORTHOPEDICS DERMATOLOGY PEDIATRICS I L 3Y financial Snapshot (FY22-25) -, I I I I I I I +23% +131% 161 Cr +91% +99% -46 days I I Op. EBITDA growth, I I Cash flow from Surge in Cash
Slide 18: Capital optimized for scalable growth
Capital optimized for scalable growth (All values in Rs. Mn) 16.1% 10.5% 1·-·-·-·1 ■ 351 6.7% 59 3.5% 231 36 139 24 93 13 I -■-■-■-· FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 - NWC (Rs.Mn) % of Sales ■ Net Working Capital cycle (Days) 1. Net Working Capital as a % of sales has sharply reduced indicati
Slide 19: Rewarding shareholders with progressive payouts
Rewarding shareholders with progressive payouts 125%* 60% 57% 100% 100% 50% 80% 34% ROE ROCE 23% 17% 14% 12% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 Dividend Rate% Enabling Shareholder’s Return • Robust cash flows enabling higher distributions. • Zero-debt and high ROCE business model supporting sus
Slide 20: Growth Outlook
Growth Outlook The 3-Pronged Growth Strategy Outlook – FY26 and Beyond New Product Launch FY25 410 bps 29%+ Niche, Innovation driven OPM growth Launch 4-6 products annually, driving market Revenue Growth (Pre- ESOP) engagement and revenue FY26 Outlook Volume Growth 20%+ 15%+ Sales Force Empowe
Slide 21: About the Company
About the Company 18
Slide 22: Strong Presence in Key Therapies
Strong Presence in Key Therapies Gynecology Orthopedics 10th as per CMARC RPM in CVM 2nd as per CMARC RPM in CVM Regular connect with 25,000 of 32,000 01 02 Regular connect with 75% practicing Gynecologist Orthopedics Leaders in Progesterone therapeutic Gynaecology Orthopedics Strong pre
Slide 23: Building A High-impact Asset Light Model
Building A High-impact Asset Light Model Capital Intensive Activities - Out-Sourced 0- -- Ideation PAN-India Distribution o In-house Ideation For Research & Contract o 900+ Medical Reps for Innovative Drug Concepts. Development Manufacturing brand promotion 1-2 New Product Launches o 18 stocking poi
Slide 24: Strategic Pillars
Strategic Pillars Innovation - Large, well Niche Molecules, trained Work Dominant Market Force of 900+ Share Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 21
Slide 25: Network of Experienced Medical Reps
Network of Experienced Medical Reps Well trained and experienced 9 9 900+ medical representatives across all their therapeutic areas 9 1.25+ Lacs. Pharmacies to ensure efficient product delivery 9 States across the nation served 9 28 through extensive distribution network Prescribers trust, endorsed
Slide 26: Real World Impact: Beyond The Bottom Line
Real World Impact: Beyond The Bottom Line Shaping the Driving Empowering Transforming Future Menopause Women Through Hygiene Access Awareness MySakhi Expanding outreach Deliver impactful A dedicated website Built modern with self-testing kits, virtual sessions on offering educational sanitation comp
Slide 27: 5-Year journey in a nutshell
5-Year journey in a nutshell (All values in Rs. Mn) Revenue (Rs Mn) Operating EBITDA (Rs Mn)* 2,687 579 2,367 2,176 2,087 434 1,879 364 250 191 T FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 PAT (Rs Mn) Margins built to last 375 22% 18% 17% 267 225 EBITDA 171 189 12% 14% margin 10% 11% 11% 9% 9
Slide 28: Driving Growth with Efficiency
Driving Growth with Efficiency (All values in Rs. Mn) Net Cash Position (Rs. Mn) Free Cash Flow (Rs. Mn) 541 476 1,526 1,456 349 1,146 274 534 252 59 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 * 25 *Net of Rs. 928 Mn spent on acquisition
Slide 29: Thank You
Thank You Feel free to reach out to us if you have any questions. JAGSONPAL PHARMACEUTICALS LTD. INVESTOR RELATIONS Corporate Office: Nimai Tower, 3rd Floor, Soumya Chhajed Plot No. 412-415, Phase-IV, Udyog Vihar, Email: soumya@goindiaadvisors.com Gurugram -122015, Haryana (India) Ph: +91 8619707750
Jagsonpal Pharmaceuticals — FY2025 Earnings Presentation on 6ix